Alessandra Decina

Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests

Leave a Comment / Press Release /

NEW YORK and PARIS, Dec. 9, 2021  — Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused […]

Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests Read More »

Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)

Leave a Comment / Press Release /

New York, November 9th, 2021 — Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET® -AML test for early detection

Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML) Read More »

Prof. Patrizia Paterlini-Brechot – Rarecells, Inc. – embarks on the search for the First Cell to beat cancer

1 Comment / Uncategorized /

We are delighted to join the prestigious The Oncology Think Tank, initiated by Prof. Azra Raza – Director of the MDS Center at Columbia University in New York, USA. We aim to provide patients with blood tests that diagnose cancer well before the moment medical imaging analyses are able to detect the tumor mass, making cancer

Prof. Patrizia Paterlini-Brechot – Rarecells, Inc. – embarks on the search for the First Cell to beat cancer Read More »

Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS

Leave a Comment / Press Release /

PARIS, April 6, 2021 /PRNewswire/ — Rarecells Inc., a leading Liquid Biopsy company is pleased to announce the development of an innovative and accurate targeted digital single-cell Next-Generation Sequencing (scNGS) for single-nucleotide variant (SNV) method to detect mutant genes of pancreatic ductal adenocarcinoma (PDAC) circulating tumor cells (CTC) enriched by the ISET® technology.  A peer-reviewed article, published in

Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS Read More »

Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

Leave a Comment / Press Release /

We are enthusiastic to share the results of the Professor Karin Ried and researchers of the National Institute of Integrative Medicine (Melbourne, Australia).  PARIS, Oct. 28, 2020 /PRNewswire/ — Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men

Press release : ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells Read More »

2nd Liquid Biopsies Congress – Global Exchange

Leave a Comment / Uncategorized /

Attend the Keynote presentation ”New non-invasive approaches for early diagnosis and follow up of invasive cancers” of Prof. Patrizia Paterlini-Bréchot, CSO of Rarecells Diagnostics, during the 2nd Liquid Biopsies Congress, which will be held virtually and free to attend upon registration. Save the date: Thursday 2020, 08th October at 4:20 pm. For more information and

2nd Liquid Biopsies Congress – Global Exchange Read More »

Press release : ISET® technology applied to DLA products from NSCLC patients identified more CTC than other systems

Leave a Comment / Press Release /

We are enthusiastic to share the results of the research conducted by Dr Tamminga from the University of Groningen. ISET Technology applied to DLA products. This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream.   PARIS, Sept. 24, 2020 /PRNewswire/ — Rarecells Diagnostics (France), a leading liquid biopsy company,

Press release : ISET® technology applied to DLA products from NSCLC patients identified more CTC than other systems Read More »

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019 Conference

Leave a Comment / Uncategorized /

Attend the Keynote presentation ” Clinical Applications of Circulating Tumor Cells in Predictive Oncology ” of Prof. Patrizia Paterlini-Bréchot, CSO of Rarecells Diagnostics, during the Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019 Conference in Rotterdam. Save the date: Wednesday 2019, 30th October at 09:45 am. For more information visit: https://www.selectbiosciences.com/conferences/biographies.aspx?speaker=1472017&conf=EXLBPEU2019

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019 Conference Read More »

Rarecells, Inc. USA

Rarecells Diagnostics

Paris, France

  • contact@rarecells.com
  • +33 (0) 1 40 61 56 02
Facebook-f Linkedin-in Envelope

You're one click away from your download !

Please enter the requested information below and click SEND

No Thanks!

You're one click away from your download !

Please enter the requested information below and click SEND

No Thanks!

You're one click away from your download !

Please enter the requested information below and click SEND

No Thanks!